Essential hypertension, a major health problem worldwide, is a disease generally considered to require life-long treatment. However, evidence suggests that hypertension is caused by specific phenotypic changes caused by the combination of genetic and environmental factors. Thus, in principle, hypertension could be prevented by prevention of these phenotypic changes. Animal data indicate that early treatment that blocks the renin-angiotensin system have long-term effects after treatment withdrawal. Here we report on two human trials that are testing whether early treatment (with the AT1-antagonist, candesartan) is able to have a persistent effect after stopping treatment: the Danish Hypertension Prevention Project and Trial of Prevention of Hypertension.
Department of Pharmacology, University of Aarhus, Aarhus, Denmark, *Division of Hypertension, University of Michigan Medical Center, Ann Arbor, Michigan, USA, and University of Texas, Southwestern Medical Center, Dallas, Texas, USA
Correspondence to Professor Michael J. Mulvany, Department of Pharmacology, University of Aarhus, University Park 240, 8000 Aarhus C., Denmark; e-mail: firstname.lastname@example.org
The DHyPP and TROPHY studies are both supported by AstraZeneca, Mölndal, Sweden